Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions: Drug: avelumab
Drug: Bempegaldesleukin
Drug: talazoparib
Drug: enzalutamide

First Posted Date: 2019-08-09

Last Posted Date: 2021-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 3

Registration Number: NCT04052204

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇧🇪
GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk, Antwerpen, Belgium

and more 2 locations

A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2019-08-06

Last Posted Date: 2023-06-09

Lead Sponsor: Pfizer

Target Recruit Count: 1349

Registration Number: NCT04047121

Locations: 🇺🇸
Pfizer, Collegeville, Pennsylvania, United States

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-06865571 400 mg Immediate Release (IR) in Fed State
Drug: PF-06865571 50 mg Modified Release (MR) in Fed State
Drug: PF-06865571 400 mg MR in Fed State
Drug: PF-06865571 400 mg MR in Fasted State

First Posted Date: 2019-08-02

Last Posted Date: 2019-11-27

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04044053

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Be-bru, Belgium

Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia

Phase 1

Terminated

Conditions: Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia

Interventions: Drug: Ceftazidime-avibactam

First Posted Date: 2019-08-01

Last Posted Date: 2022-09-09

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT04040621

Locations: 🇨🇳
Chang Gung Memorial Hospital-Linkou, Taoyuan City, Taiwan
🇨🇳
Taipei Municipal Wanfang Hospital, Taipei, Taiwan
🇨🇳
Chengdu Women's and Children's Central Hospital, Chengdu, Sichuan, China

and more 1 locations

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Crisaborole 2%
Drug: Vehicle

First Posted Date: 2019-07-31

Last Posted Date: 2023-03-08

Lead Sponsor: Pfizer

Target Recruit Count: 620

Registration Number: NCT04040192

Locations: 🇺🇸
Skin Care Research LLC, Boca Raton, Florida, United States
🇮🇱
The Chaim Sheba Medical Center, Ramat - Gan, Israel
🇺🇸
Colorado Springs Dermatology Clinic, PC, Colorado Springs, Colorado, United States

and more 40 locations

Precedex Special Investigation (in Pediatric Patients)

Completed

Conditions: Sedation

Interventions: Drug: Dexmedetomidine Hydrochloride

First Posted Date: 2019-07-31

Last Posted Date: 2024-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 111

Registration Number: NCT04040439

Locations: 🇯🇵
Pfizer Japan Local Country Office, Tokyo, Japan

A Renal Impairment Study for PF-06651600

Phase 1

Terminated

Conditions: Renal Impairment

Interventions: Drug: PF-06651600

First Posted Date: 2019-07-30

Last Posted Date: 2021-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT04037865

Locations: 🇺🇸
Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Miami, Florida, United States
🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸
Prism Clinical Research, LLC, Saint Paul, Minnesota, United States

Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Completed

Conditions: Carcinoma
Renal Cell

Interventions: Drug: Sunitinib
Drug: Axitinib

First Posted Date: 2019-07-26

Last Posted Date: 2023-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 684

Registration Number: NCT04033991

Locations: 🇬🇧
Pfizer UK, London, United Kingdom

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

Phase 2

Completed

Conditions: Respiratory Tract Infection

Interventions: Biological: RSV vaccine
Biological: Placebo

First Posted Date: 2019-07-25

Last Posted Date: 2022-10-18

Lead Sponsor: Pfizer

Target Recruit Count: 1153

Registration Number: NCT04032093

Locations: 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸
Abrazo West Campus Hospital, Goodyear, Arizona, United States
🇺🇸
Cullman Clinical Research, Inc, Cullman, Alabama, United States

and more 145 locations

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06651600
Drug: Ethinyl estradiol (EE) and levonorgestrel(LN)

First Posted Date: 2019-07-12

Last Posted Date: 2019-11-15

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT04018274

Locations: 🇺🇸
Quotient Sciences Screening Office, Coral Gables, Florida, United States
🇺🇸
Quotient Sciences, Miami, Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy